Healthegy Team

Craig SimakCo-Founder &

Executive Producer

Danielle SilvaManager, Planning &

Production

Maureen LinnemannSponsor Relations

Manager

Tom SalemiContent Director

Karin EnglundMarketing Team Leader

Joanne CarrilloController

Mario EscamillaVisual Designer

Most Recent OIS Meetings

5th Annual OIS@ASCRSNew Orleans, LA

May 5th, 2016

7th Annual OIS@AAOLas Vegas, NV

November 12th, 2015

Inaugural OIS@ASRS

Global Ophthalmic Pharmaceutical Market Revenues by Indication

Market Scope ®

Source: Market Scope Estimates; Courtesy Dave Harmon. http://market-scope.com/

2015 20200

5

10

15

20

25

30

35

9.3

16.5

4.7

6.1

3.1

3.7

3.8

4.2

$20.9 Bn

$39.5 Bn

Anti-VEGF/Retina

Glaucoma

Dry Eye

All Other

Global Ophthalmic Procedures - 2015

Vitrectomies

Laser Photocoagu-lation

IVT InjectionsCataract, RLE,

Phakic IOLs

Laser Refractive

Glaucoma Filtering, Shunts, MIGs

Glaucoma Laser

All Other

Market Scope ®

Source: Market Scope Estimates; Courtesy Dave Harmon. http://market-scope.com/

Retina – 25.7M

24.2M

VC Investment By Ophthalmic Indication (1999-2015*)

*2015 figures through OctoberSOURCE: Strategic Transactions

AMD

Glau

com

aVi

sion

Corre

ction

Cata

ract

/IOL

Dry E

yeOt

her/

Undisc

lose

dDi

abeti

c Mac

ular

Edem

a

Uvei

tisDr

ug D

eliv

ery

Visio

n re

stor

ation

Conj

uncti

vitis

Diag

nosti

c

0100200300400500600700800900

1,0001,1001,200

0

10

20

30

40

50

60

49

37

2119

1214

10 7

1410

34

Priv

ate

Plac

emen

ts ($

M)

Number of Deals

Number of Deals

RETINA

ASRS Leadership and Honorary Co-Chairs

Tarek S. Hassan, MDPresident

Honoary OIS Co-Chair

Mark S. Humayun, MD, PhDPresident-Elect

Honorary OIS Co-Chair

Jill F. Blim, MSExecutive Vice President

OIS Attendees Over Time

InauguralOIS@ASRS

( ~ 28 K ; ~ 4 % )

( ~ 8 K ; ~ 7 % )

( ~ 1.8 K ; ~ 13 % )

OIS@ASRS Attendees – 2016 ( ~ 225 )

29%

25%

14%

11%

10%

6%4%

Networking Lunch Host

Vince Anido, Jr, PhDCEO & Chairman of the Board

Thomas A. MitroPresident and COO Richard J. Rubino

CFO

Casey C. Kopczynski, PhDCSO

The Retina

Retina Company Showcase

Moderated By:

Tracy Saxton, PhD Investment DirectorRoche Venture Fund

Financing EnvironmentIntroduced By:

Gilbert H. Kliman, MD Managing Director InterWest Partners

Trends in Private Company Financing & Exits in Ophthalmology

Jonathan Norris, Managing Director Silicon Valley Bank

Public Market Trends in Ophthalmology

Andrew Gitkin, Head, West Coast Investment BankingPiper Jaffray

Innovation in Retinal Imaging: Opportunities & ChallengesPresentations

Introduced By:

William J. Link, PhD Managing Director Versant Ventures

History of OCT-A

David Huang, MD, PhD

History of Intraoperative OCT

Cynthia Toth, MD

Innovation in Retinal Imaging: Opportunities & ChallengesPanel Discussion

Moderated By:

William J. Link, PhD Managing Director Versant Ventures

Participants:

Ralf Kuschnereit, PhD, SVP Ophthalmic Systems Division

Carl Zeiss Meditec AG

Kester Nahen, PhD Managing Director

Heidelberg Engineering

Heinrich Dreyer, PhD VP, Medical Division Leica Microsystems

Ryan Bouchard Director, Medical Devices

Ora

Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies)

Company PresentationsModerated By:

Tarek Hassan, MD

Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies)

Panel DiscussionParticipants:

Trex Topping, MD John Thompson, MD

Jay Duker, MD Joshua Schimmer, MD Senior Research Analyst

Piper Jaffray

Co-Moderated By:

Tarek Hassan, MD

Gilbert H. Kliman, MD Managing Director InterWest Partners

Emerging Approaches to Combination Therapies in AMD & DMECompany Presentations

Moderated By:

Mark Humayun, MD, PhD

Emerging Approaches to Combination Therapies in AMD & DMEPanel Discussion

Participants:

Pravin Dugel, MD Donald J. D’Amico, MD

Mark Blumenkranz, MD Adnan Butt Biotech Analyst

RBC Capital Markets

Co-Moderated By:

Mark Humayun, MD, PhD

Emmett T. Cunningham Jr., MD, PhD, MPH

PartnerClarus

Peter Kaiser, MD

Masters of the IndustryModerated By:

Jim MazzoGlobal President of Ophthalmology

Carl Zeiss Meditec

Participants:

Ludwin Monz, PhD President & CEO

Carl Zeiss Meditec AG

Tony Adamis, MD Global Head, I2O & Metabolism,

Clinical Science Genentech

Frederic GuerardWorldwide Business Franchise Head,

Ophthalmology Novartis

William J. Link, PhD Managing Director Versant Ventures

Networking Reception Host